Carbapenems in the USA: Focus on doripenem

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 5, 2007, Pages 793-809

  Lister, Philip D ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbapenem; Doripenem; Ertapenem; Imipenem; Mechanism of action; Meropenem; Pharmacodynamics; Pharmacokinetics; Resistance; Toxicity

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BETA LACTAMASE; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CARRIER PROTEIN; CEPHALOSPORIN DERIVATIVE; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; PENICILLIN BINDING PROTEIN; PENICILLIN G; PORIN; THIENAMYCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BINDING AFFINITY; BURKHOLDERIA CEPACIA; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; ELECTROENCEPHALOGRAPHY; ENTEROCOCCUS FAECIUM; ENZYME SYNTHESIS; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INHIBITION KINETICS; INJECTION SITE REACTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; POSTANTIBIOTIC EFFECT; RASH; RECEPTOR BINDING; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCUS; STENOTROPHOMONAS MALTOPHILIA; STRUCTURE ACTIVITY RELATION; UNITED STATES; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CARBAPENEMS; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; THIENAMYCINS; UNITED STATES;

EID: 35348947949     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.5.793     Document Type: Review

References (130)

1. Chow JW, Fine MJ, Schlaes DM et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115, 585-590 (1991).
2. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9, 1065-1078 (1987).
3. Phelps CE. Bug/drug resistance: sometimes less is more. Med. Care 27, 194-203 (1989).
4. Kahan JS, Kahan FM, Goegelman R et al. Thienamycin, a new β-lactam antibiotic: I. Discovery taxonomy, isolation and physical properties. J. Antibiot. 32, 1-12 (1979).
5. Cassidy PJ. Novel naturally occurring β-lactam antibiotics - a review. Dev. Ind. Microbiol. 22, 181-209 (1981).
6. Miyashita K, Massova I, Mobashery S. Quantification of the extent of attenuation of the rate of turnover chemistry of the TEM-1 β-lactamase by the α-1R-hydroxyethyl group in substrates. Bioorg. Med. Chem. Lett. 6, 319-322 (1996).
7. Christensen BG. Structure activity relationship in β-lactam antibiotics. In: β-lactam Antibiotics. Mode of Action, New Developments and Future Prospects. Salton MEJ, Schockman GD (Eds). Academic Press, London, UK 101-125 (1981).
8. Leanza WJ, Wildonger JK, Miller TW, Christensen BG. N-acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal β-lactam antibiotics. J. Med. Chem. 22, 1435-1436 (1979).
9. Kropp H, Sundelof JG, Hajdu R, Kahan FM. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase: dehydropeptidase-I. Antimicrob. Agents Chemother. 22, 62-70 (1982).
10. Birnbaum J, Kahan FM, Kropp H. Carbapenems: a new class of β-lactam antibiotics. Discovery and development of imipenem cilistatin. Am. J. Med. 78(6A), 3-21 (1985).
11. Noorby SR, Alestig K, Bjornegard B et al. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by co-administration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob. Agents Chemother. 23, 626-629 (1983).
12. Sunagawa M, Matsumura H, Inoue T, Fukasawa N, Kato M. SM-7338 a new carbapenem antibiotic: structure-activity relations and physiochemical properties. Presented at: 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, NY, USA, October 4-7, 1987.
13. Wise R. In vitro and pharmacokinetic properties of the carbapenems. Antimicrob. Agents Chemother. 30, 343-349 (1986).
14. Hammond ML. Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties. J. Antimicrob. Chemother. 53(Suppl. 2), ii7-ii9 (2004).
15. Firtsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect. 11, 974-984 (2005).
16. Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. 48, 1384-1396 (2004).
17. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity agaisnt contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. 54, 144-154 (2004).
18. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 43, 424-427 (1999).
19. Iso Y, Irie T, Nishino Y, Motokawa K, Nishitani Y. A novel 1β- methylcarbapenem antibiotics, S-4661: synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ythio)-1β-methylcarbapenems. J. Antibiot. 49, 199-209 (1996).
20. Davies TA, Shang W, Bush K, Flamm RK. Binding of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Francisco, CA, USA, 17-20 September 2006 (Abstract C1-0039).
21. Edwards JR. Meropenemia microbiological overview. J Antimicrob. Chemother. 36(Suppl. A), 1-17 (1995).
22. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J. Antimicrob. Chemother. 52, 331-344 (2003).
23. Bonfiglio, G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin. Investig. Drugs 11, 529-544 (2002).
24. Sumita Y, Fukasawa M, Okuda T. Comparison of two carbapenems, SM-7338 and imipenem, affinities for, penicillin-binding proteins and its release from these proteins and morphological changes. J. Antibiot. 43, 314-320 (1990).
25. Hashizume T, Ishino F, Nakagawa J. Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) In vitro binding to the penicillin binding proteins of E. coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli. J. Antibiot. 37, 394-400 (1984).
26. Kitzis MD, Acar JF, Gutman L. Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect and against staphylococci. J Antimicrob. Chemother. 24(Suppl. A), 125-132 (1989).
27. Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins and stability to hydrolysis by β-lactamases. J. Antimicrob. Chemother. 35, 75-84 (1995).
28. Kohler J, Dorso KL, Young K et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniaeand Echerichia coli clinical isolates. Antimicrob. Agents Chemother. 43, 1170-1176 (1999).
29. Fujimura T, Kimura Y, Yoshida Y et al. In vitro antibacterial activity of doripenem, a novel parenteral carbapenem. Jpn. J. Chemother. 53 (Suppl. 1), 56-69 (2005).
30. Davies TA, Shang W. Bush K, Flamm RK. Activity of doripenem and comparators against Streptococcus pneumoniae U.S. clinical isolates with defined substitutions in penicillin-binding proteins (PBP) 1a, PBP 2b, and PBP 2x. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Francisco, CA, USA, 17-20 September 2006 (Abstract C1-0038).
31. Sumita Y, Fukosawa M, Okuda T. Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus. Antimicrob. Agents Chemother. 34, 484-486 (1990).
32. Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-12 (1998).
33. Craig W, Ebert SC. Killing and regrowth of bacteria in vitro a review. Scand. J. Infect. Dis. 74, 63-70 (1991).
34. Craig W. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22, 89-96 (1995).
35. Vogelman B, Gudmundsson S, Leggett J et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158, 831-847 (1988).
36. Roosendaal R, Bakker-Woundenberg IAJM, van den Berg JC, Michel MF. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J. Infect. Dis. 152, 373-378 (1985).
37. DeRyke CA, Lee Sy, Kuti JL, Nicolau DP. Optimizing dosing strategies of antibacterials utilizing pharmacodynamic principles: impact on the development of resistance. Drugs 66, 1-14 (2006).
38. Hanberger H, Nilsson LE, Nilsson M, Maller R. Post-antibiotic effect of β-lactam antibiotics on Gram-negative bacteria in relation to morphology, initial killing, and MIC. Eur. J. Clin. Microbiol. Infect. Dis. 10, 927-934 (1991).
39. Bustamante CI, Drusano G, Tatem BA, Standiford HC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26, 678-682 (1984).
40. Gudmundsson S, Vogelman B, Craig W. The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J. Antimicrob. Chemother. 18(Suppl. E), 67-73 (1986).
41. Nadler HL, Pitkin DH, Sheikh W. The post-antibiotic effect of meropenem and imipenem on selected bacteria. J. Antimicrob. Chemother. 24(Suppl. A), 225-231 (1989).
42. Odenholt I. Ertapenem: a new carbapenem. Expert Opin. Inveitig. Drugs 10, 1157-1166 (2001).
43. Totsuka K, Kikuchi K. In vitro postantibiotic effect and in vivo antimicrobial activity of doripenem, a new carbapenem. Jpn. J. Chemother. 53(Suppl. 1), 51-55 (2005).
44. Pryka RD, Haig GM. Meropenem: a new carbapenem antimicrobial. Ann. Pharmacother. 28, 1045-1054 (1994).
45. Jones RN. Review of the in vitro spectrum of activity of imipenem. Am. J Med. 78(Suppl. 6A), 22-32 (1985).
46. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J. Antimicrob. Chemother. 55, 944-949 (2005).
47. Tsuji M, Yoshikazu I, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42, 94-99 (1998).
48. Wexler HM, Engel AE, Glass D, Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob. Agents Chemother. 49, 4413-4417 (2005).
49. Hanson ND. AmpC β-lactamases: what do we need to know for the future? J. Antimicrob. Chemother. 52, 2-4 (2003).
50. Hanson ND, Sanders CC. Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae. Curr. Pharm. Des. 5, 881-894 (1999).
51. Sanders CC. Chromosomal cephalosporinases responsible for multiple resistance to new β-lactamase antibiotics. Annu. Rev. Microbiol. 41, 573-593 (1987).
52. Sanders CC, Sanders EC. Emergence of resistance during therapy with newer β-lactam antibiotics: role of inducible β-lactamases and implications for the future. Rev. Infect. Dis. 5, 639-648 (1983).
53. Sanders CC, Sanders EC. β-lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin. Infect. Dis. 15, 824-839 (1992).
54. Perez F, Hanson ND. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40, 2153-2162 (2002).
55. Jacoby GA. β-lactamase nomenclature. Antimicrob. Agents Chemother. 50, 1123-1129 (2006).
56. Reisbig MD, Hossain A, Hanson ND. Factors influencing gene expression and resistance for Gram-negative organisms expressing plasmid-encoded ampCgenes of Enterobacter origin. J. Antimicrob. Chemother. 51, 1141-1151 (2003).
57. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52, 71-74 (2005).
58. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob. Agents Chemother. 48, 1313-1319 (2004).
59. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14, 933-951 (2001).
60. Jacoby GA. Genetics of extended-spectrum β-lactamases. Eur. J. Clin. Microbiol. Infect. Dis. 13 (Suppl. 1), 2- 11 (1994).
61. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48, 1-14 (2004).
62. Paterson DL, Rossi F, Baquero F et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J. Antimicrob. Chemother. 55, 965-973 (2005).
63. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18, 657-686 (2005).
64. Bradford PA, Bratu S, Urban C et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis. 39, 55-60 (2004).
65. Bratu S, Mooty M, Nichani S et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49, 3018-3020 (2005).
66. Bratu S, Tolaney P, Karumudi U et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56, 128-132 (2005).
67. Woodford N, Tierno PM, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. 48, 4793-4799 (2004).
68. Bratu S, Landman D, Haag R et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in Brooklyn, NY. epidemiology and recommendations for detection. Arch. Intern. Med. 165, 1430-1435 (2005).
69. Bratu S, Landman D, Alam M, Tolentino E, Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother. 49, 776-778 (2005).
70. Hossain A, Ferraro MJ, Pino RM et al. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob. Agents Chemother. 48, 4438-4440 (2004).
71. Miriagou V, Tzouvelekis LS, Rossiter S et al. Imipenem resistance in Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 47, 1297-1300 (2003).
72. Livermore DM, Oakton KJ, Carter MW. Activity of ertapenem versus Enterobacteriaceae with potent β-lactamases. Antimicrob. Agents Chemother. 45, 2831-2837 (2001).
73. Koh TH, Sng LH, Babini GS. Carbapenem-resistant Klebsiella pneumoniae in Singapore producing IMP-1 β-lactamase and lacking an outer membrane porin. Antimicrob. Agents Chemother. 45, 1939-1940 (2001).
74. Jacoby GA, Mills DM, Chow N. Role of β-lactamases and porins in resistance to ertapenem and other β-lactams In Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48, 3203-3206 (2004).
75. Martinez-Martinez L, Pascual A,. Hernandez-Alle S. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. 43, 1669-1673 (1999).
76. Elliott E, Brink AJ, van Greune J et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum β-lactamase. Clin. Infect. Dis. 42, 95-98 (2006).
77. Trias J, Nikaido, H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34, 52-57 (1990).
78. Trias J, Nikaido H. Protein D2 channel of Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. J. Biol. Chem. 265, 15680-15684 (1990).
79. Pirnay J-P, Vos DD, Mossialos D et al. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ. Microbiol. 4, 872-882 (2002).
80. Wolter DJ, Hanson ND, Lister PD. Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol. Lett. 236, 137-143 (2004).
81. Yoneyama H, Nakae T. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37, 2385-2390 (1993).
82. Kohler T, Michea-Hamzehpour M, Henz U. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudamonas aeruginosa. Mol. Microbiol. 23, 345-354 (1997).
83. Ochs MM, McCusker MP, Bains M, Hancock RE. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Andtimicrob. Agents Chemother. 43, 1085-1090 (1999).
84. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. J. Antibiot. 59, 220-228 (2006).
85. Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959-964 (2000).
86. Masuda N, Sakagawa E, Ohya S et al. Substrate specificities of MexAB-OprM, MexCD-OprJ and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 3322-3327 (2000). -
87. Gotoh N, Tsujimoto H, Tsuda M et al. Characterization of the MexC-MexD-OprJ multidrug efflux system in δ-mexA-mexB- oprM mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 42, 1938-1943 (1998).
88. Lister P. AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among pseudomonas aeruginosa isolates overexpressing the mexCDpoprJ efflux pump. Antimicrob. Agents Chemother 49, 4763-4766 (2005).
89. Fukuda H, Hosaka M, Iyobe S et al. nfx C-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39, 790-792 (1995).
90. Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39, 645-649 (1995).
91. Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin. Infect. Dis. 40, S105-S114 (2005).
92. Kohler T, Epp SF, Curty LK, Pechere JC. Characterization of MexT, the regulator of the MexE-.MexF-OprN multi-drug efflux system of Pseudomonas aeruginosa. J. Bacteriol. 181, 6300-6305 (1999).
93. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudamonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50, 1633-1641 (2006).
94. Masuda N, Sakagawa E, Ohya S, Gotoh N, Nishino T. Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to β-lactams due to reduced expression of the AmpC β-lactamase. Antimicrob. Agents Chemother, 45, 1284-1286 (2001).
95. Masuda N, Ohya S. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36(9), 1847-1851 (1992).
96. Hori T, Nakano M, Kimura Y, Murakami K. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 20, 91-96 (2006).
97. Physicians Desk Reference. Thomson (2005).
98. Floren L, Wikler MA, Kilfoil T, Ge Y. A Phase 1 open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics of doripenem administered intravenously to subjects with renal impairment. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA, October 30-November 2, 2004 (Abstract A-17).
99. Floren L, Wikler MA, Kilfoil T, Ge Y. A Phase 1, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of prolonged-infusion regimens of doripenem in healthy subjects. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA, October 30-November 2, 2004 (Abtract A-16).
100. Van Wart S, Bhavnani SM, Phillips L, Wikier MA, Ambrose PG. Population pharmacokinetics of doripenem. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA, October 30-November; 2, 2004 (Abstract A-18).
101. Majumdar AK, Musson DG, Birk KL et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. 46, 3506-3511 (2002).
102. Mattoes HM, Kud JL, Drusano GL, Nicoiau DPCT. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Ther. 26, 1187-1198 (2004).
103. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq M-P, Tulkens PM. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46, 2327-2332(2002).
104. Nicasio AM, Quintiliani R, DeRyke CA, Kuti JL, Nicolau DP. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem. Ann. Pharmacother. 41, 1077-1081 (2007).
105. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob. Agents Chemother. 49, 461-463 (2005).
106. Psathas P, Kuzmission A, Ikeda K, Ihara S. Stability of doripenem for Injection (500 mg) in Representative Infusion Fluids and Containers. Presented at: American Society of Health System Pharmacists. San Francisco, CA, USA, June 24-27, 2007 (Abstract 57E).
107. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K. Treatment of complicated intra-abdominal infections: doripenem versus meropenem. Presented at: European Congress on Clinical Microbiology and Infectious Diseases. Munich, Germany, March 31-April 3, 2007 (Abstract P834).
108. Malafaia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, September 17-20, 2006. (Abstract L-1564b).
109. Calandra GB, Brown KR, Grad LC et al. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. Am. J. Med. 78(Suppl. 6A), 73-78 (1985).
110. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem: a review of its antibacterial activity pharmacokinetics and clinical efficacy. Drugs 50, 73-101 (1995).
111. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J. Antimicrob. Chemother. 36(Suppl. A), 207-223 (1995).
112. Calandra GB, Ricci FM, Wang C, Brown KR. The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials. J Clin. Pharmacol. 28, 120-127 (1988).
113. Rodloff AC, Goldstein EJC, Torres A. Two decades of imipenem therapy. J. Antimicrob. Chemother. 58, 916-929 (2006).
114. Chambers HF, Neu HC. Penicillins. In: Principals and Practice of Infectious Diseases Mandell GL, Bennett JE, Dolin R (Eds). Churchill Livingstone, NY, USA 223-246 (1995).
115. Calandra GB, Wang C, Aziz MA, Brown KR. The safety profile of imipenem/ cilastatin: worldwide clinical experience-based on 3470 patients. J. Antimicrob. Chemother. 18(Suppl. E), 193-202 (1986).
116. Wang C, Calandra GB, Aziz MA, Brown KR. Efficacy and safety of imipenem/ cilastatin: a review of worldwide experience. Rev. Infect. Dis. 7(Suppl. 3), S528-S536 (1985).
117. Sodhi M, Axtell SS, Callahan Shekar R. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J. Antimicrob. Chemother. 54, 1155-1157 (2004).
118. Prescott WA, DePestel DD, Ellis JJ, Regal RE. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin. Infect. Dis. 38, 1102-1107 (2004).
119. Calandra GB, Lydick E, Carrigan J. Weiss L, Guess H. Factors predisposing to seizures in seriously ill patients receiving antibiotics: experience with imipenem/cilastatin. Am. J. Med. 84, 911-918 (1988).
120. De Sarro A, De Sarro, GB, Ascioti C, Nistico G. Epileptogenic activity of some β-lactam derivatives: structure-activity relationship. Neuropharmacology 28, 359-365 (1989).
121. Williams PD, Bennett DB, Comereski CR. Animal model for evaluating the convulsive liability of β-lactam antibiotics. Antimicrob. Agents Chemother. 32, 758-760 (1988).
122. Barrons RW, Murray KM, Richey RM. Populations at risk for perticillin-induced seizures. Ann. Pharmacother. 26, 26-29 (1992).
123. Day LP, Goudie J, Nishiki K, Williams PD. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol. Lett. 76, 239-243 (1995).
124. Shimada J, Kanemitsu K, Shoji Y, Nakashio S, Yanagawa A. A comparative study of the convulsant activity of carbapenems and β-lactams. Drugs Exp. Clin. Res. 18, 377-381 (1992).
125. Sunagawa. M, Matsumura H, Sumita. Y, Nouda H. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J. Antibiot. 48, 408-416 (1995).
126. Horiuchi M, Kimura M, Tokumura M et al. Absence of convulsive liability of doripenem, a new carbapenern antibiotic, in comparison with β-lactam antibiotics. Toxicolgy 222, 114-124 (2006).
127. Job ML, Dretler RH. Seizure activity with imipenem therapy: incidence and risk factors. DICP. Ann. Pharmacother. 24, 467-469 (1990).
128. Pestotnik SL, Classen DC, Evans RS, Stevens LE, Burke JR Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann. Pharmacother. 27, 497-501 (1993).
129. Norrby SR, Gildon KM. Safety profile: of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand. J. Infect. Dis. 31, 3-10 (1999).
130. Keating GM, Perry CM. Ertapenem. a review of its use in the treatment of bacterial infections. Drugs 65, 2151-2178 (2005).